Objective: Rare coexistence of disease or pathology Background: Fluid overload-associated large B-cell lymphoma (FO-LBCL) is a recently described malignant lymphoma that presents with serous effusions in the pleura, peritoneum, and/or pericardium but without an identifiable lymphoma mass. This report describes the case of an 80-year-old man who presented with a pleural effusion and describes the approach to diagnosis and management of FO-LBCL. Case Report: We present a case of an 80-year-old man who presented with right pleural effusion and shortness of breath at work. Initial radiological assessment suggested a pleural effusion on the right side, without an identifiable mass, given the patient's symptoms and imaging characteristics. Subsequently, he underwent a pleural fluid puncture and biopsy. Based on the initial pathological assessment, malignant lymphoma, a non-epithelial tumor, was considered likely, but differentiation from reactive proliferative cells was difficult, given the patient's symptoms and cytologic characteristics. Postoperatively, histopathological examination and immunohistochemistry confirmed a diagnosis of FO-LBCL. After 1 year of follow-up, the condition had progressed and the patient died due to recurrence. Conclusions: This report has presented a case of FO-LBCL in an elderly man with pleural effusion and described how this rare and recently described lymphoma was diagnosed and managed.
Hepatoblastoma (HB) is the most common malignant solid tumor of the liver in children and is a fatal disease with a poor prognosis. Therefore, indicators that can be used for the early prediction of the HB prognosis are necessary. Sodium glucose cotransporter 2 (SGLT2) is a glucose transporter protein present in the proximal renal tubules. Studies have shown that SGLT2 is associated with the occurrence of tumors and is upregulated in various tumors. Peroxiredoxin 4 (PRDX4) is an antioxidant enzyme with a secretory function and is located in the cytoplasmic endoplasmic reticulum. Recent reports have suggested that it is closely related to the development and prognosis of various cancers. To some degree, this is highly suggestive of the interplay between SGLT2 and PRDX4. In the present study, clinical data and post-surgical paraffin-embedded specimens from 75 HB patients were collected, and hematoxylin and eosin and immunohistochemical staining of SGLT2 and PRDX4 were used to analyze their expression and correlation with the clinicopathological features and prognosis. We found that low SGLT2 and high PRDX4 expression predicted a significantly shorter survival and worse clinical condition in HB patients. Furthermore, when low SGLT2 expression was combined with high PRDX4 expression, the event-free survival and overall survival were significantly reduced. Univariate and multivariate Cox proportional hazards analyses showed that low SGLT2 and high PRDX4 expression in HB were independent prognostic factors for the survival after surgical resection. The immunohistochemical combination of low SGLT2 and high PRDX4 expression can independently predict a poor prognosis in HB patients.
10 March 2026 in Microscopy Research and Technique
Kidney disease (KD) is a major health problem, and metabolic disorders contribute to diabetic nephropathy and chronic kidney disease, in which renal epithelial cell dysfunction plays an important role. Intracellular advanced glycation end-products (AGEs) may contribute to KD progression by disrupting cellular homeostasis; however, the underlying mechanisms remain unclear. Therefore, we aimed to investigate the effects of glyceraldehyde (GA) on molecular chaperone- and autophagy-related proteins in human renal epithelial cells (HK-2), with particular attention to AGE-related processes. Administration of high-fructose corn syrup to healthy Wistar rats increased argpyrimidine immunoreactivity in the renal tubular epithelial cells, compared with that in controls, suggesting enhanced accumulation of this GA-related AGE in vivo. In HK-2 cells, GA treatment caused concentration-dependent reductions in NADPH and ATP levels, accompanied by morphological changes. High molecular weight (HMW) immunoreactive species of HSP90β, Beclin-1, and ATG7 appeared following GA treatment. GA at 1.5 mM increased LC3-I, LC3-II, and p62 levels, whereas treatment with 2 mM GA attenuated these increases. Aminoguanidine, an inhibitor of AGE formation, attenuated these GA-induced alterations. Overall, GA may induce the generation of HMW species of HSP90β and autophagy-related proteins and may contribute to altered cellular homeostasis, with AGE-related processes potentially contributing to these effects.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive behavior, therapeutic resistance, and redox imbalance. Peroxiredoxin 4 (PRDX4), an endoplasmic reticulum-localized antioxidant enzyme, has been implicated in tumor progression, but its clinical significance and redox-associated role in PDAC remain unclear. PRDX4 expression was assessed by immunohistochemistry in 128 resected PDAC specimens and correlated with clinicopathological features and disease-specific survival (DSS). Functional effects were examined in PRDX4-overexpressing PDAC cell lines. Intracellular reactive oxygen species (ROS) were evaluated under basal and oxidative stress conditions, with N-acetyl-l-cysteine (NAC) rescue. Signaling and redox-related proteins were analyzed by Western blotting. A PRDX4-transgenic mouse model was used to evaluate tumor growth, angiogenesis, and gemcitabine (GEM) responsiveness. High PRDX4 expression was associated with aggressive clinicopathological features and poor DSS. PRDX4 overexpression promoted cell proliferation and migration and reduced intracellular ROS levels. NAC treatment diminished ROS differences, supporting ROS-dependent redox modulation. PRDX4 overexpression was associated with increased ERK phosphorylation, suppressed JNK phosphorylation, increased total PI3K/AKT and p38 levels, reduced E-cadherin expression, and upregulation of NRF2 and HO-1. PRDX4 expression positively correlated with NRF2 and HO-1 in clinical specimens. In vivo, PRDX4 overexpression promoted tumor growth, increased microvessel density, and reduced GEM sensitivity. PRDX4 is associated with aggressive tumor behavior, redox adaptation, and might reduce gemcitabine responsiveness in PDAC in vivo, supporting its potential as a prognostic biomarker and a candidate molecule for future therapeutic investigation.